{
  "id": 17196635,
  "title": "AstraZeneca Q3 Profit Rises; Reconfirms FY26 Revenue, Core EPS Guidance At CER",
  "url": "https://urgent.news/2026/10/30/astrazeneca-q3-profit-rises-reconfirms-fy26-revenue-core-eps-guidance",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T07:52:47.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/astrazeneca-q3-profit-rises-reconfirms-fy26-revenue-core-eps-guidance-cer"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) reported that its third quarter profit attributable to owners of the Parent increased to $3.12 billion from $2.53 billion, prior year. Diluted earnings per $0.25 Ordinary Share was $2.00 compared to $1.62. Core EPS was $2.7",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}